Results for
"[search-keyword]"
Sponsor content
412 result(s) found, displaying 1 to 10
-
Australian Public Assessment Report (AusPAR)Arexvy is a vaccine approved for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in individuals 60 years and older
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AREXVY Recombinant Respiratory Syncytial Virus pre-fusion F protein vaccine 120 micrograms powder vial and suspension vial suspension for injection.
-
May-2024Prescription medicine evaluationActive ingredient: momelotinib dihydrochloride monohydrate.
-
Cancellation by sponsorRequested by GlaxoSmithKline Australia Pty Ltd
-
Cancellation by sponsorRequested by GlaxoSmithKline Australia Pty Ltd
-
Cancellation by sponsorRequested by GlaxoSmithKline Australia Pty Ltd
-
Apr-2024Prescription medicine evaluationActive ingredient: recombinant respiratory syncytial virus pre-fusion F protein.
-
Apr-2024Prescription medicine evaluationActive ingredient: dostarlimab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MENVEO Meningococcal (Groups A,C,W-135 and Y) Oligosaccharide CRM197 solution for injection vial.
-
Prescription medicine decision summaryArexvy (recombinant respiratory syncytial virus pre-fusion F protein) is approved for individuals 60 years and older for the prevention of lower respiratory tract disease caused by respiratory syncytial virus